Biogen's (BIIB) Anti-LINGO Data Better then Expected; Stifel Affirms at 'Hold'

Teva, Intel to develop wearable technology for Huntington's disease

(Reuters) - Teva Pharmaceutical Industries Ltd (NYSE: TEVA) said on Thursday it was collaborating with Intel Corp (NASDAQ: INTC) to develop a wearable technology platform to track the progression of disease in patients with Huntington's, a fatal degenerative disorder.

The inherited condition causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability.

There are no approved drugs to alter the course of Huntington's, although there are medicines that help with symptoms. Patients typically succumb to the... More

Biogen (BIIB), AbbVie (ABBV) Announce Significant ZINBRYTA Data in NEDA vs AVONEX

A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking AVONEX® (interferon beta-1a) intramuscular injection. The findings continue to support the positive impact of ZINBRYTA on NEDA status. Additional new interim data from the long-term extension study, EXTEND, further affirm ZINBRYTAs efficacy on clinically meaningful measures of multiple sclerosis (MS) disease activity and provide additional information supporting ZINBRYTAs safety profile. These results were presented by... More